PKM and serum lipopolysaccharide activity: Our previous study demonstrated that the PKM2 inhibitor shikonin inhibits PKM2 activity and suppresses circulating IL-1β and HMGB1 levels and prevents lethality during endotoxemia and polymicrobial sepsis in mice9.